Polar Capital LLP Has $29.88 Million Stake in Regeneron Pharmaceuticals Inc (REGN)
Polar Capital LLP lifted its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 23.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,000 shares of the biopharmaceutical company’s stock after purchasing an additional 15,000 shares during the period. Polar Capital LLP owned 0.07% of Regeneron Pharmaceuticals worth $29,880,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Whittier Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 195.7% in the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 45 shares during the period. Rehmann Capital Advisory Group lifted its holdings in Regeneron Pharmaceuticals by 1,700.0% in the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 68 shares during the period. AdvisorNet Financial Inc lifted its holdings in Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 52 shares during the period. Captrust Financial Advisors purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $30,000. Finally, Intercontinental Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $33,000. Institutional investors own 66.87% of the company’s stock.
Several equities analysts have recently issued reports on REGN shares. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 16th. Oppenheimer set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 2nd. Leerink Swann set a $483.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 7th. They noted that the move was a valuation call. Goldman Sachs Group upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “conviction-buy” rating in a report on Thursday, December 13th. Finally, ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 15th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $413.76.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $5.10 by $1.74. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The firm’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.23 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current fiscal year.
In related news, VP Christopher R. Fenimore sold 1,848 shares of the firm’s stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total transaction of $663,376.56. Following the completion of the sale, the vice president now owns 9,871 shares of the company’s stock, valued at $3,543,392.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph L. Goldstein sold 1,791 shares of the firm’s stock in a transaction that occurred on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total transaction of $734,310.00. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $5,786,740. The disclosure for this sale can be found here. Insiders have sold 134,754 shares of company stock valued at $55,439,356 in the last three months. 12.42% of the stock is owned by insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Determine Your Level of Risk Tolerance
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.